Acquisition Announced

argenx SE acquisition of Forte Biosciences

US$2.2bn equity value

Announced 27 Jul 2026 · NASDAQ: FBRX · US$77.00 cash per share · 86% premium

Advisers

Forte Biosciences

Target

Financial adviser
Fairness opinion

argenx SE

Acquirer

Financial adviser
Legal adviser
Information Agent
Target
Forte Biosciences
Acquirer
argenx SE
Target based in
United States
Buyer based in
Netherlands
Sector
Biotech
Tags
Biotech, Drug Development

In the league tables

Similar deals

All biotech deals →

Sources

Suggest a correction

A missing adviser, a wrong role or a different outcome. A link to a public source helps.